Acutaas Chemicals Ltd vs Emcure Pharmaceuticals Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 05, 2026

Key Highlights

The Latest Trading Price of Acutaas Chemicals Ltd is ₹ 2655 as of 05 May 15:30 . The P/E Ratio of Acutaas Chemicals Ltd changed from 50.6 on March 2022 to 125.9 on March 2025 . This represents a CAGR of 25.59% over 4 yearsThe P/E Ratio of Emcure Pharmaceuticals Ltd changed from 29.8 on March 2025 to 29.8 on March 2025 . This represents a CAGR of 0.00% over 1 years The Market Cap of Acutaas Chemicals Ltd changed from ₹ 3642 crore on March 2022 to ₹ 9994 crore on March 2025 . This represents a CAGR of 28.70% over 4 yearsThe Market Cap of Emcure Pharmaceuticals Ltd changed from ₹ 20327 crore on March 2025 to ₹ 20327 crore on March 2025 . This represents a CAGR of 0.00% over 1 years The revenue of Acutaas Chemicals Ltd for the Mar '26 is ₹ 443.86 crore as compare to the Dec '25 revenue of ₹ 397.88 crore. This represent the growth of 11.56% The revenue of Emcure Pharmaceuticals Ltd for the Mar '26 is ₹ 2484 crore as compare to the Dec '25 revenue of ₹ 2365 crore. This represent the growth of 5.02% The ebitda of Acutaas Chemicals Ltd for the Mar '26 is ₹ 194.62 crore as compare to the Dec '25 ebitda of ₹ 155.35 crore. This represent the growth of 25.28% The ebitda of Emcure Pharmaceuticals Ltd for the Mar '26 is ₹ 493.84 crore as compare to the Dec '25 ebitda of ₹ 456.45 crore. This represent the growth of 8.19% The net profit of Acutaas Chemicals Ltd changed from ₹ 14.69 crore to ₹ 134.28 crore over 8 quarters. This represents a CAGR of 202.34% The net profit of Emcure Pharmaceuticals Ltd changed from ₹ 152.59 crore to ₹ 243.74 crore over 8 quarters. This represents a CAGR of 26.39% The Dividend Payout of Acutaas Chemicals Ltd changed from 15.19 % on March 2022 to 7.7 % on March 2025 . This represents a CAGR of -15.62% over 4 yearsThe Dividend Payout of Emcure Pharmaceuticals Ltd changed from 4.3 % on March 2021 to 17.92 % on March 2025 . This represents a CAGR of 33.04% over 5 years .

About Acutaas Chemicals Ltd

Acutaas Chemicals Limited was initially formed as partnership firm in the name of 'Ami Organics' on 3 January, 2004 at Surat, India.
The Firm converted into a Private Limited Company under the name of 'Ami Organics Private Limited' with a Certificate of Incorporation dated 12 June, 2007.
Subsequently, the Company was converted into a Public Limited Company, reflecting the change in name of the Company to 'Ami Organics Limited' on April 18, 2018.
The name of the Company has now changed to Acutaas Chemicals Limited with effect from May 15, 2025, pursuant to the receipt of Fresh Certificate of Incorporation from the Registrar of Companies. The Company is engaged in business of drugs intermediate chemicals and related activities.
The Company is one of the major manufacturers of Pharma Intermediates for certain key APIs, including Dolutegravir, Trazodone, Entacapone, Nintedanib and Rivaroxaban.

About Emcure Pharmaceuticals Ltd

Emcure Pharmaceuticals Limited was originally incorporated as Emcure Pharmaceuticals Private Limited', as a Private Company, pursuant to a Certificate of Incorporation dated April 16, 1981 issued by Registrar of Companies, Maharashtra at Bombay.
Subsequently, Company was converted into a Public Company and the name of Company was changed to Emcure Pharmaceuticals Limited', through a fresh Certificate of Incorporation issued by the RoC, Maharashtra in Pune on September 18, 2001. Emcure Pharmaceuticals an Indian pharmaceutical company engaged in developing, manufacturing and globally marketing a broad range of pharmaceutical products across several major therapeutic areas.
In India, they are present across acute and chronic therapeutic areas, and their key therapeutic areas include gynecology, cardiovascular, vitamins, minerals and nutrients, human immunodeficiency virus antivirals, blood-related and oncology/anti-neoplastics.

FAQs for the comparison of Acutaas Chemicals Ltd and Emcure Pharmaceuticals Ltd

Which company has a larger market capitalization, Acutaas Chemicals Ltd or Emcure Pharmaceuticals Ltd?

Market cap of Acutaas Chemicals Ltd is 21,901 Cr while Market cap of Emcure Pharmaceuticals Ltd is 33,844 Cr

What are the key factors driving the stock performance of Acutaas Chemicals Ltd and Emcure Pharmaceuticals Ltd?

The stock performance of Acutaas Chemicals Ltd and Emcure Pharmaceuticals Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Acutaas Chemicals Ltd and Emcure Pharmaceuticals Ltd?

As of May 5, 2026, the Acutaas Chemicals Ltd stock price is INR ₹2675.1. On the other hand, Emcure Pharmaceuticals Ltd stock price is INR ₹1785.15.

How do dividend payouts of Acutaas Chemicals Ltd and Emcure Pharmaceuticals Ltd compare?

To compare the dividend payouts of Acutaas Chemicals Ltd and Emcure Pharmaceuticals Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.